MDGL vs SMMT
MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications.
Side-by-side fundamentals
| Metric | MDGL | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $551.25 | $13.10 | |
| Market cap as of 2026-08-03 | $12.7B | $10.2B | |
| PEG as of 2026-08-03 | -134.35 | -1.08 | MDGL lower |
| Net margin as of 2026-08-03 | -27.3% | -9027.1% | MDGL higher |
| Gross margin as of 2026-08-03 | +93.1% | n/a | |
| Operating margin as of 2026-08-03 | -27.9% | -8108.3% | MDGL higher |
| ROE as of 2026-08-03 | -50.1% | -168.9% | MDGL higher |
| ROA as of 2026-08-03 | -25.4% | -141.9% | MDGL higher |
| Debt / equity as of 2026-08-03 | 0.63 | 0.00 | SMMT lower |
| Revenue growth (YoY) as of 2026-08-03 | +256.8% | n/a | |
| Beta as of 2026-08-03 | -1.05 | -1.34 | |
| 1-year return as of 2026-07-27 close | +84.7% | -54.3% | MDGL higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.